Madrigal Pharmaceuticals, Inc. (MDGL) Social Stream

Madrigal Pharmaceuticals, Inc. (MDGL): $115.33

-1.69 (-1.44%)

POWR Rating

Component Grades













Featured Post From StockTwits About MDGL

I went looking this morning at competitors/peers of $HEPA, meaning companies that are also onto NASH.

What I found made me very determined to hold it at least untill completion of Phase 2B, which will be around January 2022.
Truly, to all you guys, KNOW WHAT YOU OWN........

Look at Madrigal Pharmaceuticals ($MDGL), the only competitor to Hepion on terms of NASH.
They finished Phase 2B in december 2019 and started Phase 3 at the same time.
*So, they are practically around 1.5-2 years ahead of Hepion. * --> remember this
Madrigal's results from the Phase 1 and -2A trials were significantly positive than Hepion's results. Also, Madrigal is only focussing on NASH, whereas Hepion is focussing on NASH, HBV, COVID and HCC (liver cancer). Hepion even has a AI-platform that will reduce the cost of trials.....

Yet, Madrigal's market cap is 1.8 billion, Hepion's market cap is 135 million.
Do you understand the potential for the next 1.5-2 years?
semperfideliis, published March 30, 2021

What Else are MDGL Traders Talking About?

Other tickers frequently mentioned alongside MDGL are HEPA and ATNF.

Other Notable StockTweets About MDGL

$ATNF $ATNF is the most shorted stock in the market compared to float. Short term we have the biggest chance to squeeze and long term we are looking at 20x to 50x gain at a minimum. If this message is showing up on your board you are also under attack by short sellers... Just trying to be a good friend and help you make some money. Come do some DD... .. ... ...


Drunkcowsmoo, published March 11, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8272 seconds.